Search Results
Your search for ,Few matches 3119 pages
Showing 1051 - 1100Statins With or Without Metformin Are Associated With Increased Survival in Patients With High‑Risk Prostate Cancer
A population-based retrospective cohort study involving 12,700 patients found that men with high-risk prostate cancer who took a statin alone or in combination with metformin had reduced all-cause and prostate cancer–specific mortality. The associations between the medications and reduced...
A Clinical Trial Saved My Life
In the fall of 2009, I began experiencing some abdominal discomfort, pain in my right shoulder, and severe fatigue that were easily explained away as the result of gallstones and by my career as a paramedic. I had many of the risk factors for gallbladder disease, and both my mother and sister...
Chemotherapy and the Sweat Lodge
The ASCO Post is pleased to reproduce installments of Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays, historical...
After Training Across Three Continents, a Hematologist Leads the Wisconsin Hematology/Oncology Division
In this edition of Living a Full Life, guest editor Jame Abraham, MD, FACP, spoke with hematologist Parameswaran Hari, MD, MRCP, Chief of the Division of Hematology and Oncology at the Medical College of Wisconsin, Milwaukee. In addition, Dr. Hari holds the Armand J. Quick/William F. Stapp Chair...
Aspirin Use and Risk of Cancers of the Digestive Tract
Aspirin may be associated with a reduction in the risk of developing several cancers of the digestive tract. The largest and most comprehensive analysis to date of the link between aspirin and digestive tract cancers, published by Bosetti et al in Annals of Oncology, found reductions in the risk of ...
City of Hope Deploys Platform, Makes Study Data Accessible
A $12 million federal grant enabled City of Hope and collaborators to deploy a novel cloud-computing platform, making an immense amount of data from a historic 25-year study more accessible and user-friendly. The ongoing California Teachers Study, which began in 1995, has already given researchers...
Highlights From Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR
The Combined Annual Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) were held in Orlando, Florida, from February 19–23, 2020. The scientific program addressed the most timely issues in ...
Updates From Selected Clinical Trials in Breast Cancer
Each year, The ASCO Post asks Jame Abraham, MD, FACP, Chairman of the Department of Hematology and Medical Oncology at Taussig Cancer Institute and Professor of Medicine at the Cleveland Clinic Lerner College of Medicine, to offer his picks for the most important research presented at 2019 San...
Second-Line Lurbinectedin in Small Cell Lung Cancer
As reported in The Lancet Oncology by Trigo et al, second-line treatment with the selective oncogenic transcription inhibitor lurbinectedin showed activity in patients with small cell lung cancer included in a phase II basket trial. The trial includes cohorts representing nine different tumor...
Does Pembrolizumab Show Activity in Some Rare Cancers?
A study published by Naing et al in the Journal for ImmunoTherapy of Cancer found that treatment with pembrolizumab demonstrated acceptable toxicity and antitumor activity in patients with four types of advanced, hard-to-treat rare cancers. “Our findings that pembrolizumab has a favorable toxicity...
Practicing Oncology in the Era of COVID-19
The coronavirus-related pandemic has affected nearly every corner of the globe. What originated in one country is on course to likely affect every country in the world. In a few countries, the disease has peaked and is on the downward trend. In some, including the United States, the disease is on...
Predicting Which Patients With Ovarian Cancer May Respond to Combination PARP and PD-1 Inhibition
In some patients with advanced ovarian cancer, the combination of programmed cell death protein 1 (PD-1) and poly (ADP-ribose) polymerase (PARP) inhibitors can produce responses, but up until now, investigators have been unable to predict which patients would not benefit from the treatment and...
Survey Says: A Low-Tech Approach Leads to High-Quality Care in South Africa
An American medical student travels to rural Uganda; there, he finds most villagers walking miles to receive health care at the nearby district hospital. Upon arrival, they spend hours waiting in line. Some patients make this trip monthly. Before entering internal medicine residency, Daniel O’Neil, ...
Don’t Expect Transgender Patients to ‘Out’ Themselves
Although more transgender patients are presenting to breast centers for imaging, many “report significant social stigma when seeking care,” according to a study in the Journal of Breast Imaging.1 Reported verbal abuse and other forms of harassment “can lead to transgender patients concealing their...
AML Pioneer and Giant, Clara D. Bloomfield, MD, FASCO, Dies at 77
Physicians and scientists interested in acute myeloid leukemia (AML) have lost one of the community’s shining lights with the death of Clara D. Bloomfield, MD, FASCO, on March 1, 2020, at age 77 years. Dr. Bloomfield is well known for her more than 50 years of groundbreaking research in blood...
A Cello for Michayla
The ASCO Post is pleased to reproduce installments of Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays, historical...
Cancer During Pregnancy: Whose Moral Compass to Follow?
As has often been written, “Cancer is the greatest equalizer.” It tends to strike its victims regardless of their financial status. In low- and middle-income countries, however, the impact of poverty on the treatment of cancer is strikingly conspicuous. It is the major catalyst for delay in seeking ...
Oncologists on the Front Lines of COVID‑19
Coronavirus disease 2019 (COVID-19) is dramatically affecting health-care systems. This is the first in a series of interviews The ASCO Post will conduct with oncologists, to learn what they and their cancer centers are doing to deal with the crisis. In this article, we talk with John Cole, MD, a...
A Message From the FDA OCE for Patients With Cancer and Health-Care Providers on COVID-19
On March 23, the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) issued the following statement: The FDA OCE recognizes that patients with cancer constitute a vulnerable population at risk of contracting the coronavirus disease (COVID-19). While everyone’s daily lives...
TAPUR Basket Study: Biomarker-Driven Treatment Strategies Yield Benefits in Colorectal Cancer
Positive findings on the potential benefit of molecularly targeted drugs in patients with advanced colorectal cancer were presented at the 2020 Gastrointestinal Cancers Symposium, validating the purpose of ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) study.1-3 TAPUR, the first...
Conference Highlights From the 2020 Gastrointestinal Cancers Symposium
This past January, the 2020 Gastrointestinal Cancers Symposium was held in San Francisco. More than 3,600 individuals attended and more than 900 abstracts and posters were presented. Among the highlights presented at the meeting and reported in the pages of The ASCO Post, several studies in...
PSMA PET/CT May Have Major Impact on Treatment of Patients With Prostate Cancer
Prostate cancer experts speaking at the 2020 Genitourinary Cancers Symposium alluded to the fact that prostate-specific membrane antigen (PSMA) positron-emission tomography (PET)/computed tomography (CT) scanning is more sensitive than conventional imaging for the detection of occult lesions in men ...
Surveillance for Second Malignant Neoplasms and Cardiac Dysfunction in Childhood Cancer Survivors
An analysis of the Childhood Cancer Survivor Study reported in the Journal of Clinical Oncology by Yan et al found that adherence to Children’s Oncology Group (COG) recommended surveillance for second malignant neoplasms and cardiac dysfunction in high-risk childhood cancer survivors is ...
Therapy Is Keeping My Metastatic Breast Cancer Manageable
Despite being vigilant about adhering to my annual schedule of screening mammography, in 2002, I was diagnosed with stage III triple-negative breast cancer. The diagnosis scared me, and I wondered if I was going to die. Determined to do what I could to survive the cancer, I underwent aggressive...
Building Onco-Primary Care to Close the ‘Black Hole’ in Cancer Survivorship Care
When the landmark report from the Institute of Medicine, From Cancer Patient to Cancer Survivor: Lost in Transition, was published in 2006, there were 10 million cancer survivors in the United States.1 Meant to raise awareness of the medical, functional, and psychosocial consequences of a cancer...
Selected ASH Abstracts on Novel Treatments in Acute Lymphoblastic Leukemia
To complement The ASCO Post’s continued comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapies for newly diagnosed and relapsed or refractory acute...
Treating Patients With Chronic Lymphocytic Leukemia in 2020
With the availability of a number of effective targeted agents for the treatment of chronic lymphocytic leukemia (CLL), the question arises whether chemotherapy still has a role in treating this malignancy. At the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, CLL...
Expert Point of View: Charles G. Drake, MD, PhD
In an interview with The ASCO Post, Charles G. Drake, MD, PhD, expounded on the results of the COSMIC-021 trial. Dr. Drake is Division Director for GU Oncology, Co-Director of the Cancer Immunotherapy Program, and Co-Leader of the Tumor Biology and Microenvironment Program at the Herbert Irving...
ASCO’s TAPUR Study: Biomarker-Driven Treatment Paying Off in Colorectal Cancer
New data presented at the 2020 Gastrointestinal Cancers Symposium are validating the purpose of ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) study, a multibasket trial that matches patients’ genomic alterations to commercially available targeted therapies. The aim is to learn...
Vitamin D Supplementation May Protect Against Checkpoint Inhibitor–Induced Colitis
Vitamin D supplementation prior to starting immune checkpoint inhibitor therapy may significantly reduce the odds of developing colitis, according to a study conducted at Harvard Medical School. Although this was a retrospective chart review, the association was relatively strong in the...
Expert on Public Health and Policy Looks at Precision Oncology
A study published in JAMA Oncology found that 31 genome-targeted anticancer agents were in use as of January 2018.1 To shed light on the current state of precision oncology, The ASCO Post recently spoke with David M. Cutler, PhD, the Otto Eckstein Professor of Applied Economics in the Department of ...
Adjuvant Ado-Trastuzumab Emtansine vs Paclitaxel Plus Trastuzumab in Early HER2-Positive Breast Cancer
Results of the randomized, phase II ATEMPT trial showed that the antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) failed to demonstrate improved safety when compared with paclitaxel plus trastuzumab as adjuvant therapy in patients with stage 1 HER2-positive breast cancer. These results of...
Early FDG-PET Allows De-escalation of Chemotherapy in Metastatic Seminoma
In patients with metastatic seminoma, the early use of 18F-fluorodeoxyglucose (FDG)–positron-emission tomography (PET) to risk-stratify patients enabled the de-escalation of chemotherapy, avoiding treatment with bleomycin—one of the most toxic drugs used to treat this cancer—and excessive doses of...
Active Hexose Correlated Compound
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Gary Deng, MD, PhD, and Jyothirmai Gubili, MS, focus on active hexose...
More Choices, More Flexibility With New Maintenance of Certification Pathway
Beginning this year, oncology specialists will have the opportunity to pursue a more flexible and less burdensome path to maintaining recertification. The American Board of Internal Medicine (ABIM)/ASCO Medical Oncology: Learning & Assessment (MOLA) is a lower-stakes Maintenance of...
Immunogenomic Profiling of Osteosarcoma
Comprehensive profiling of tumor samples taken from patients with osteosarcoma showed that multiple factors contribute to the traditionally poor responses observed with immune checkpoint inhibitor treatment in patients with this malignancy, according to new research published by Wu et al in Nature...
Ask Patients About Their Use of Dietary Supplements
A study finding that that patients who use antioxidant supplements, iron, and vitamin B12, before and during chemotherapy may be at increased risk of breast cancer recurrence and mortality confirms concerns about the use of these supplements. It also “absolutely reinforces the importance of asking...
Cancer Has Made Me the Person I Am, and I’m Grateful
The only clue that I was harboring a life-threatening cancer came as I was driving to a golf lesson in the fall of 2006, and I casually rubbed the left side of neck and felt a tiny bump. Although I wasn’t alarmed at the time, I did point out the mass to my primary care physician when I met with...
Using Machine Learning to Prompt Serious Illness Conversations
Despite research showing that among patients with cancer, early advance care planning conversations lead to care that is in alliance with patients’ goals and wishes, especially at the end of life,1 most patients die without having discussions about their treatment goals and end-of-life preferences ...
Bispecific Antibody Shows Activity in Post–CAR T-Cell Therapy for Non-Hodgkin Lymphoma
Mosunetuzumab, an investigational bispecific antibody, demonstrated activity in preliminary studies of patients with non-Hodgkin lymphoma (NHL), including those who are refractory to or relapsed after third-line chimeric antigen receptor (CAR) T-cell therapy. With further study, mosunetuzumab,...
States With Highest Rates of Cutaneous Melanoma Due to Ultraviolet Exposure
A new study found a wide state-by-state variation in rates of melanoma caused by ultraviolet (UV) exposure, with highest rates in several states on the east and west coasts (including Hawaii), but also a few landlocked states (including Utah, Vermont, and Minnesota). The report, published by Islami ...
ASCO/CCO Update Guideline for Selecting Systemic Treatment in Stage IV NSCLC Without Driver Mutations
ASCO and Cancer Care Ontario (CCO) have published an update to a joint guideline on systemic therapy for stage IV non–small cell lung cancer (NSCLC) without driver mutations.1 “The treatment of stage IV NSCLC has become increasingly more complicated, and, with the advent of immunotherapy and the...
Overcoming Barriers to Alleviating Cancer-Related Pain in Ethiopia
According to the World Health Organization (WHO), approximately 70% of deaths from cancer occur in low- and middle-income countries, where late-stage presentation and inaccessibility to diagnosis and treatment are common.1 In the sub-Saharan African country of Ethiopia, cancer is becoming an...
Genetic Mutations in Donor Stem Cells May Affect Hematopoietic Transplant Recipients
A new study on hematopoietic stem cell transplantation from Washington University School of Medicine in St. Louis suggests that extremely rare, harmful genetic mutations present in healthy donors’ stem cells—though not causing health problems in the donors—may be passed on to patients with cancer...
Expert Point of View: Michael Jain, MD, PhD
Michael Jain, MD, PhD, Assistant Member in the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center, Tampa, Florida, commented on Dr. Kilgore’s findings. Dr. Jain was coauthor of a study by the U.S. Lymphoma CAR T Consortium that presented real-world data...
Denial’s Many Faces
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Doctoring in the Digital Age: Modern Stressors, Ancient Strategies to Cope
In my 45 years of practicing hematology/oncology at a major urban academic medical center, I have observed a sea change in daily practice that contributes to physician burnout. Although the emotional stresses of caring for seriously ill people play a part in physician burnout, I find the daily...
A Retired Oncologist Remains Involved in the Science and Policy of Oncology
The history of medicine once was featured in medical school curricula. That is becoming less common due to time restriction and the increased prevalence of more technical topics. However, the importance of the history of medicine cannot be overstated: It shapes every aspect of our cultural,...
Novel Guideline Addresses the Clinical Utility of Molecular Biomarkers in Localized Prostate Cancer
In men, prostate cancer has the highest incidence of any neoplasm and is the second-leading cause of cancer-related mortality. A plethora of tissue-based biomarkers are available to inform the diagnosis and prognosis for men with newly diagnosed, clinically localized prostate cancer. However, to...
Gabrielle Rocque, MD, MSPH, Followed Three Generations of Doctors Into a Career in Medicine
In 2017, breast cancer expert Gabrielle Rocque, MD, MSPH, received an American Cancer Society Mentored Research Scholar Grant for her work in enhancing shared decision-making for patients with advanced breast cancer. “I come from three generations of physicians,” shared Dr. Rocque. “My father (Dr. ...
